# DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

> **NCT03837873** · PHASE2 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 118 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Transformed Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Etoposide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide
- **DRUG:** Lenalidomide
- **DRUG:** Cisplatin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03837873
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-21
- **Primary completion:** 2023-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03837873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03837873, "DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03837873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*